-
Mashup Score: 0
Tracy Proverbs-Singh, MD, and Steven Lee-Kong, MD, discuss recent updates in the management of gastrointestinal malignancies, with a focus on colorectal cancer and the crucial role of precision medicine in guiding treatment decisions.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
During a Targeted Oncology™ Case-Based Roundtable™ event, Garrett B. Sherwood, MD, discussed biopsy and treatment approaches for a patient diagnosed with T2aN2M0, stage IIIA adenocarcinoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Garrett B. Sherwood, MD, discussed biopsy and treatments for a patient diagnosed with T2aN2M0, stage IIIA adenocarcinoma. #lcsm | @NovantHealth https://t.co/RkVr6Or7o5
-
-
Mashup Score: 0
Patients treated with VT1021 for recurrent glioblastoma were found to have immune markers associated with response to treatment in a phase 1/2 study.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Patients with recurrent #glioblastoma who responded to VT1021 had beneficial and sustained changes to immune markers associated with response. #bcsm | @ClevelandClinic https://t.co/2oo7KjCBUc
-
-
Mashup Score: 0Study Design and Inclusion Criteria of the EV-103 Study in Advanced Urothelial Carcinoma - 1 year(s) ago
Jonathan E. Rosenberg, MD, explains the study design and patient inclusion criteria of the phase 2 EV-103 study investigating combination enfortumab vedotin plus pembrolizumab for the treatment of patients with metastatic or locally advanced urothelial carcinoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Jonathan E. Rosenberg, MD, on the study design and patient inclusion criteria of the phase 2 EV-103 study. #blcsm | @DrRosenbergMSK @MSKCancerCenter @OncBrothers https://t.co/xU20fk3MH6
-
-
Mashup Score: 0Growing Use of Bispecifics for the Treatment of Multiple Myeloma - 1 year(s) ago
George Nahas, DO, discusses ongoing research that may shape the future treatment landscape of multiple myeloma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
WATCH: George Nahas, DO, discusses ongoing research that may shape the future treatment landscape of multiple myeloma. #mmsm | @BaptistHealthSF @BHCancerCare @MiamiCancerInst https://t.co/CCeZaso8bw
-
-
Mashup Score: 0
Funda Meric-Bernstam, MD, discusses fam-trastuzumab deruxtecan-nxki and the evaluation of the agent in the phase 2 DESTINY-PanTumor02 trial.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
WATCH: Funda Meric-Bernstam, MD, discusses trastuzumab deruxtecan and the evaluation of the agent in the phase 2 DESTINY-PanTumor02 trial. #bcsm | @MDAndersonNews https://t.co/7HgzleF618
-
-
Mashup Score: 0Tara Graff: ‘My Heart Has Always Been in Research’ - 1 year(s) ago
In an interview with Targeted Oncology, Q2 2023 Oncology Icons honoree, Tara Graff, DO, MS, discusses her path to community oncology from academia, and hopes to continue to advance community-based research in the future.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Q2 2023 Oncology Icons honoree, Tara Graff, DO, MS, discusses her path to community oncology from academia, and hopes to continue to advance community-based research in the future. @missioncancer_ https://t.co/PomLltpxmK https://t.co/WzxGFdXQ6E
-
-
Mashup Score: 0
The acceptance of a new drug application for rivoceranib plus camrelizumab by the FDA is supported by data from the phase 3 CARES 310 study in patients with unresectable hepatocellular carcinoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The #FDA has assigned a PDUFA target action date of May 16, 2024, for the combination of rivoceranib plus camrelizumab for unresectable hepatocellular carcinoma. #HCC #lcsm https://t.co/7cwlEHpN8R
-
-
Mashup Score: 1Physicians Discuss Roles of Later-Line Therapies in DLBCL - 1 year(s) ago
During a Targeted Oncology™ Case-Based Roundtable™ event, Matthew Matasar, MD, MS, discussed with oncologists how they use loncastuximab tesirine and tafasitamab/lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A discussion with Matthew Matasar, MD, MS, on using loncastuximab tesirine and tafasitamab/lenalidomide in patients with relapsed/refractory diffuse large B-cell #lymphoma. #DLBCL #lymsm | @DrMatasar @RutgersCancer https://t.co/LKM8ZtGFIq
-
-
Mashup Score: 0
In most key prespecified molecularly defined subsets of patients with pretreated KRAS G12C–mutated non–small cell lung cancer, sotorasib continued to demonstrate consistent benefit vs docetaxel.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ICYMI: Most key prespecified molecularly defined subsets of patients with pretreated KRAS G12C–mutated #NSCLC had a consistent benefit with sotorasib vs docetaxel. #ASCO23. | @MDAndersonNews https://t.co/8b18bpYVHe
-
WATCH: Tracy Proverbs-Singh, MD, & Steven Lee-Kong, MD, discuss updates in the management of GI malignancies, focusing on colorectal cancer & the role of precision medicine. #gicsm | @JTCancerCenter @columbiacancer @HMHNewJersey https://t.co/1DD8g0i7NF